Results 31 to 40 of about 6,146 (182)

Comparison of Adverse Kidney Outcomes With Empagliflozin and Linagliptin Use in Patients With Type 2 Diabetic Patients in a Real-World Setting

Frontiers in Pharmacology, 2021
Background: To compare the effects of empagliflozin and linagliptin use on kidney outcomes of type 2 diabetes mellitus (T2DM) patients in a real-world setting.Methods: The study involved a propensity score-matched cohort comprising new users of ...
Yueh-Ting Lee, Chien-Ning Hsu, Chien-Ning Hsu, Chung-Ming Fu, Shih-Wei Wang, Chiang-Chi Huang, Lung-Chih Li, Lung-Chih Li   +7 more
doaj   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Efficacy and safety of empagliflozin for treating neutropenia and neutrophil dysfunction in paediatric patients with glycogen storage disease type Ib: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Glycogen storage disease type Ib (GSD‐Ib) is a rare genetic disorder causing neutropenia and neutrophil dysfunction in children. G‐CSF has been the primary treatment, but emerging data support the potential of empagliflozin, an SGLT2 inhibitor, as a promising investigational option.
Elizabeth Iwasyk, Ryan Jin, Fabio Tuzzolino, Giusy Ranucci, Donatella Madonia, Alessio Provenzani   +5 more
wiley   +1 more source

Empagliflozin: a new strategy for nephroprotection in diabetes

Сахарный диабет, 2017
Empagliflozin, an inhibitor of sodium–glucose symporter type 2 (SGLT2), is a new class of antidiabetic agents with numerous pleiotropic effects. The review summarises data on the influence of empagliflozin on the structural and functional changes ...
Anton Ivanovich Korbut, Vadim Valer'evich Klimontov   +1 more
doaj   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Empagliflozin Suppresses the Differentiation/Maturation of Human Epicardial Preadipocytes and Improves Paracrine Secretome Profile

JACC: Basic to Translational Science, 2023
Summary: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce epicardial adipose tissue (EAT) in humans, enhancing cardioprotective effects on heart failure and atrial fibrillation.
Masayuki Takano, MD, Hidekazu Kondo, MD, PhD, Taisuke Harada, MD, Masaki Takahashi, MD, Yumi Ishii, MD, PhD, Hirochika Yamasaki, MD, Tong Shan, MD, PhD, Kumiko Akiyoshi, MD, PhD, Takashi Shuto, MD, PhD, Yasushi Teshima, MD, PhD, Tomoyuki Wada, MD, PhD, Kunio Yufu, MD, PhD, Hidenori Sako, MD, PhD, Hirofumi Anai, MD, PhD, Shinji Miyamoto, MD, PhD, Naohiko Takahashi, MD, PhD   +15 more
doaj   +1 more source

Emulating Six Cardiovascular Outcome Trials of Antidiabetic Drugs in Individuals with Type 2 Diabetes: Analyses Based on Real‐World Databases from Korea and Taiwan

Clinical Pharmacology &Therapeutics, EarlyView.
With the increasing volume of clinical evidence derived from large‐scale Asian real‐world data (RWD) and the growing interest in its use in regulatory decision‐making, it is important to conduct benchmarking exercises that evaluate whether studies using Asian RWD can generate similar conclusions as randomized controlled trials (RCTs).
Hwa Yeon Ko, Philip C. M. Au, Michael Chun‐Yuan Cheng, Ching‐Lung Cheung, Ahhyung Choi, Miyuki Hsing‐Chun Hsieh, Han Eol Jeong, Edward Chia‐Cheng Lai, Brian Meng‐Hsun Li, Kenneth K. C. Man, Jeremy A. Rassen, Daniel Hsiang‐Te Tsai, Shirley V. Wang, Ian C. K. Wong, Ju‐Young Shin, Sohee Park   +15 more
wiley   +1 more source

Direct Cardiac Actions of the Sodium Glucose Co‐Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure‐Overload Heart Failure

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background We determined if the sodium glucose co‐transporter 2 inhibitor empagliflozin attenuates pressure overload‐induced heart failure in non‐diabetic mellitus mice by direct cardiac effects and the mechanisms involved. Methods and Results Male C57BL/
Xuan Li, Qingguo Lu, Yunguang Qiu, Jussara M. do Carmo, Zhen Wang, Alexandre A. da Silva, Alan Mouton, Ana C. M. Omoto, Michael E. Hall, Ji Li, John E. Hall   +10 more
doaj   +1 more source

Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction [PDF]

, 2021
Massar Omar, J. Steen Jensen, Mulham Ali, Peter Frederiksen, Caroline Kistorp, Lars Videbæk, Mikael Kjær Poulsen, Christian Tuxen, Sören Möller, Finn Gustafsson, Lars Køber, Morten Schou, Jacob Eifer Møller   +12 more
openalex   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source